Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Robert Watson, a NIHR Academic Clinical Fellow in the laboratory of Benjamin Fairfax. Robert was successful in his application for a CRUK pre-doctoral research bursary.

Headshot of Robert WatsonPre-doctoral research bursaries are awarded biannually by Cancer Research UK to “provide short-term funding to allow clinicians and other health professionals to get involved in research projects early in their career”. This scheme was ideal for Robert Watson, a junior doctor with an interest in academic research. He is currently taking a year out from his clinical training to conduct research in the laboratory of Benjamin Fairfax at the MRC WIMM, and is interested in applying for a PhD at a later date. “This CRUK grant will support my research this year” explains Rob “It will give me a chance to experience research and develop my skills, and hopefully gather preliminary data that will help me apply for a PhD”.

The laboratory of Dr Benjamin Fairfax (Department of Oncology) is examining the genetic changes that accompany the treatment of cancer with immunotherapies. During his time in the lab, Robert will be using sequencing techniques to investigate changes to the T cell repertoire during checkpoint inhibitor treatments. “I am very keen to work in the area of immunoncology and to further develop my skills in genetic medicine and computational biology, so this projects fits well with the lab’s strategy and my own personal aims”, says Robert. The successful bid will provide £25,000 towards the project’s research expenses.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Seven research groups secure LEAF Sustainability Awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.

Blood tests may predict response to immunotherapy for melanoma

A study from the Fairfax lab provides new insight into the factors that determine patient response to Immune Checkpoint Blockers, a common immunotherapy treatment for melanoma.

New Fellowship of the Association of Cancer Physicians

Many congratulations to Prof Adrian Harris (Department of Oncology), who has become a Fellow of the Association of Cancer Physicians.

New “molecular fibres” may help cells repair DNA

Research by the Blackford group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.

MRC WIMM researchers talk about their research on rare diseases

To mark rare disease day we asked our researchers to tell us more about the rare conditions that they study, and why their research is important.